

## POSTER SESSIONS

Poster Hall open from 7 am-7 pm; all posters will be available for viewing for the duration of the conference

### WEDNESDAY 2/17/10 • 2-4 pm

52. Cellular Restrictions: APOBEC
53. Cellular Restrictions: TRIM5 and Novel Factors
54. Cellular Restrictions: Tetherin and Vpu
55. Viral Co-factors and Cellular Restrictions
62. HIV Evolution *in vivo*
63. Evolution of HIV Co-receptor Usage
73. CTL Epitopes and Immune Control
74. Novel Insights into HLA Alleles and CD8 T Cell Control
75. New Factors Associated with CD8 T Cell Function
80. Modulating CD8 T Cells to Control Virus Replication
84. New Insights from Neuroimaging
85. Mechanisms of Neuropathogenesis
90. Molecular Epidemiology: Evolution, Subtype Distribution, and Viral Diversity
100. Plasma HIV RNA Monitoring: Suppression and Persistent Viremia
101. Keys to Successful Outcomes on ART
104. Activity and Escape from HIV Entry Inhibitors
110. Evaluation of Sample Storage Technology
113. Prevalence and Consequences of Transmitted Drug Resistance
116. Mechanisms of Activity and Failure of ART
118. Pharmacokinetics and Pharmacodynamics of Entry Inhibitors
119. Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of NRTI and NNRTI
123. Hepatitis B: Epidemiology and Prevention
124. Hepatitis B: Treatment
125. Acute Hepatitis C Infection
127. Hepatitis C: Predictors and Determinants of Response to Therapy and Its Complications
128. Hepatitis C Therapy: ART Interactions
135. Cardiovascular Disease: Pathogenesis
136. Predictors of Cardiovascular Risk and Carotid Intima-media Thickness
137. Progression of Atherosclerosis: Role of Inflammation and T Cell Activation
138. Cardiovascular Events: Assessment, Predictors, and Outcomes
139. Abacavir and Cardiovascular Disease: Search for a Mechanism
140. Dyslipidemia and Fat Changes: ART Effects
141. Fat Pathogenesis, Measurement, and Interventions
142. Complications of HIV Disease: Epidemiology and Predictors of Mortality
143. Complications: Role of Genetic Markers and Mitochondrial DNA
148. Immune Responses to KSHV/HHV-8
159. *Clostridium difficile*, Leprosy, Leishmania, and Cryptococcal Disease
160. Swine Flu Meets HIV
161. Influenza: Incidence and Prevention
162. Pneumococcal Vaccine Responses
171. Neurodevelopmental Outcomes in Children
172. Metabolic Complications and Toxicities in Children
173. ART Pharmacokinetics, Safety, and Efficacy in Children
178. Factors Influencing PMTCT Implementation
184. Persistence of Resistance and Treatment Outcomes in Women after Single-dose Nevirapine
185. HIV Drug Resistance in Breastfeeding Infants Exposed to ART
189. Improving Estimates of HIV-1 Incidence
192. Preclinical and Animal Studies of Microbicides/PrEP
193. New Insights on Male Circumcision
194. Insights into Post-exposure Prophylaxis
195. New HIV Prevention Strategies and Modeling of Impact
196. Risk Behaviors for HIV Infection
197. HIV Disease Progression

### THURSDAY 2/18/10 • 2-4 pm

56. New Insights into Virus Replication: Co-factors and Virus Entry
57. Virus-Host Cell Interaction: Studies on Macrophages
58. Therapeutic Strategies for Nef
61. Viral Decay Dynamics with ART
64. Impact of Treatment Intensification on HIV Reservoirs and Immune Activation
66. HIV-Cell Interaction *in vivo*
67. Determinants of Slow Progression of HIV Disease
69. CD4 T Cell Functions and Immune Recovery
70. What Monkey Models Can Teach Us about HIV Infection
71. NK Cells and ADCC: Linking Innate and Adaptive Immunity
72. New Markers of Immune Dysfunction and Recovery
81. Novel Approaches to Modulate CD4 Cell Infection and Survival
86. Neuropathy and Locomotor Disorder
88. Infection and Immune Activation of CNS Compartments
91. Molecular Epidemiology: Dual/Superinfection and Viral Recombinants
94. Host Genetics of HIV Infection: Novel Co-factors, Risk Alleles, and Biomarkers
95. Insights into Factors Affecting Acute HIV Infection
96. Biomarkers and Treatment during Acute HIV Infection
99. ART: New Agents and Novel Approaches
105. Prediction of HIV Co-receptor Use
106. Resistance to Reverse Transcriptase Inhibitors
114. Changing Prevalence of Multidrug Resistance
115. Adherence-Drug Resistance Relationships
120. Antiretroviral Agent Penetration into Genital Secretions
129. Hepatitis C: Metabolic and Vascular Interactions
130. Hepatitis Immunology
131. Predictors of Liver Fibrosis
132. Hepatitis: Cirrhosis, Cancer, and Transplant
144. Renal Disease: Mechanisms and Outcomes
145. Renal Disease: Incidence Outcomes and Mechanisms of Disease
149. Risk Factors and Outcomes for AIDS-related Malignancies
156. OI Prophylaxis
157. IRIS: Incidence and Pathogenesis
158. Malaria and HIV
163. Response to ART in Resource-limited Countries
166. Survival of HIV-infected Children in Africa
167. Response to First-line ART in Children
168. HIV Drug Resistance after Treatment Failure in Children
169. Screening for HIV and TB Co-infection in Adolescents
176. Impact of ART on Disease Pathogenesis in Children
179. Antiretroviral Regimens, Viral Response, and MTCT Outcomes
180. TB Screening and Impact in PMTCT
182. New Insights into Molecular Mechanisms of MTCT
186. Infant Outcome after Prenatal ART Exposure
187. ART Outcomes among Women
188. Contraception Use and Drug Interactions
190. New HIV-1 RNA Assays and Reagents
198. Identifying Persons at Risk for HIV Infection
200. ART and Transmission

### FRIDAY 2/19/10 • 2-4 pm

59. Virus-Host Cell Interaction: Impact of Virus on Host Cell Processes
60. New Insights into Virus Replication: Integration, Assembly, and Viral Latency
65. HIV Reservoirs
68. Biomarkers of HIV Disease and Death
76. Exposed Uninfected Individuals: What's New
77. New Discoveries on Neutralizing Antibodies
78. New Information on Dendritic Cells and HIV
79. Role of the Gut Mucosa in HIV Immunopathogenesis
82. Neutralizing Antibodies: Induction and Impact
83. New Approaches to Mucosal Vaccination
87. HIV-associated Neurocognitive Disorder Predictors and Co-morbidities in the ART Era
89. NeuroAIDS Treatment Issues and Controversies
92. Molecular Epidemiology: Analysis of HIV Transmission Patterns
93. Impact of KIR/HLA on HIV Infection
97. Molecular Characterization of HIV Transmission and Acute Infection
98. HIV Transmission and the Mucosa
102. First Line of Defense: ART in Resource-limited Settings
103. Life Expectancy on ART
107. Resistance to Integrase Inhibitors
108. Resistance to Protease and Maturation Inhibitors
109. Detection of Minority Resistance Mutations
111. Genotypic Assays for HIV Drug Resistance
112. Phenotypic Assays for HIV Drug Resistance
117. Strategies to Prevent HIV Drug Resistance
121. Pharmacokinetics and Drug Interactions of Integrase Inhibitors
122. Pharmacokinetics and Drug Interactions of Protease Inhibitors
126. Hepatitis C: Epidemiology and Outcomes
133. Hepatitis B and C: The Next Chapter in the Management of HIV in Resource-limited Countries
134. Hepatitis E and GBV-C
146. Bone Disease: Risk Factors
147. Got Milk? Vitamin D Deficiency Prevalence and Associations
150. Cervical and Anal Cancer: Screening, Prevalence, and Therapy
151. Diagnostics: TB and *Pneumocystis jirovecii* Pneumonia
152. TB Screening: Strategies and Diagnostic Testing
153. TB Incidence: Impact of ART
154. TB Outcomes: HIV, ART, and Immune Mechanisms
155. Multidrug-resistant TB
164. Treatment and Retention in Resource-limited Countries
165. Malnutrition and Nutritional Supplementation: Outcomes
170. HIV-related Complications and Co-infections in Children
174. Response to Protective Vaccines in Children
175. Immune Response to Perinatal HIV Infection
177. Diagnostics for HIV Infection in Exposed Infants
183. ART Pharmacokinetics and Safety during Pregnancy and Breastfeeding
191. New Diagnostic Technologies
199. Identifying HIV Incidence
201. Identifying HIV Infection
202. Mental Health, Substance Abuse, and HIV in Resource-limited Countries
203. HPV and HIV
204. HIV and STD